Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

MMF and Calcineurin Inhibitor Withdrawal in CAN

This study has been terminated.
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by:
University Hospital Muenster
ClinicalTrials.gov Identifier:
NCT00204230
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted

September 12, 2005
September 12, 2005
October 1999
Not Provided
course of renal function over 35 weeks
Same as current
No Changes Posted
  • after 35 weeks of follow up:
  • incidence of
  • -acute rejections
  • -infections
  • -malignomas
  • -gastrointestinal disorders
  • development of blood pressure over 35 weeks
  • number of antihypertensive drugs
  • lipid state at entry and after 35 weeks
  • blood glucose ,HBA1c at entry and after 35 weeks
  • uric acid at entry and after 35 weeks
  • Comparison of the development of 1/creatinine within each group at entry and 35 weeks after therapy conversion
  • area under the curve (AUC) determination of mycophenolic acid (MPA)
  • vessel wall changes of the carotid arteries IMD , compliance, distensibility and hemodynamic parameters CO, CI, at entry and after after cni withdrawal and MMF addition
Same as current
Not Provided
Not Provided
 
MMF and Calcineurin Inhibitor Withdrawal in CAN
Randomized Controlled Study: Effect of Mycophenolatmofetil in Patients With Histologically Proven Chronic Allograft Nephropathy

Prospective, randomised study: Effect of mycophenolatmofetil (MMF) and CNI withdrawal in patients with histologically proven chronic allograft nephropathy Indication: change in immunosuppressive treatment of chronic allograft nephropathy (CAN)after renal transplantation Hypothesis: Antimetabolite MMF is able to stop progression of CAN and improve blood pressure/ metabolic parameters and structural vessel wall changes

Primary Target:effects of CNI withdrawal and MMF on renal function: stabilisation and/or improvement Secondary Targets: Incidence of adverse events Evaluation of the calcineurin inhibitor free MMF treatment effects on blood pressure, lipids, glucose metabolism and on structural and functional vesselwallchanges Method:open prospective, randomized two-tailed, monocentric study

Prospective, randomised study: Effect of mycophenolatmofetil in patients with histologically proven chronic allograft nephropathy

SYNOPSIS

Indication: change in treatment to improve the course of chronic allograft nephropathy

Method: open prospective, randomized two-tailed, non blinded monocentric study

Follow up period: 35 Weeks

Number of patients: 2 x 86 patients

Inclusion criteria: • Written informed consent

  • Reduction of graft function: Increase of serum creatinine >/= 0,1mg/dl/month in the previous 6 months before start of the study and/or new occurrence or increasing proteinuria in the last 6 months before start of the study
  • Serum creatinine < 4 mg/dl
  • Biopsy within the last 3 months
  • histologically proved chronic allograft nephropathy (graft glomerulopathy, chronic rejection ,interstitial fibrosis, tubular atrophy, vascular arteriosclerosis,hyalinosis)
  • >1 year after renal allografting
  • At least 5 mg/day of prednisolone or equivalent dose

Exclusion criteria: • Malignomas

  • Gravidity or Lactation
  • Participation in other studies
  • Severe infections
  • Florid gastrointestinal Ulcer
  • Age between 18 and 70 years
  • Leukopenia with less that 3000/l leucocytes, Anaemia Hb  9 g/dl
  • Therapy with mycophenolatmofetil in the past 6 months
  • Acute rejections in the apst 6 months

Study protocol:

Phase I: Week 1.-3. Conversion to Triple-Drug-Therapy, consisting of Mycophenolatmofetil, corticosteroids (e.g. prednisolone) and ciclosporine A or Tacrolimus

1. Addition of Mycophenolatmofetil (MMF) to the previous immosuppressive treatment, consisting of ciclosporine A (CsA) or Tacrolimus (FK506) in combination with corticosteroids, e.g. prednisolone (P). In the case that azathioprine (AZA) had been given, AZA is replaced by MMF. The therapy with MMF starts 3 days after the elimination of azathioprine.

The addition of MMF follows the following scheme if nothing else is indicated:

  1. week: 1g/day, 2.week: 1,5g/day, 3.week: 2g/day
  2. Ciclosporine A bzw. tacrolimus: Target whole trough blood levels:

    CsA: 80-120 ng/ml (HPLC) FK506: 4-7 ng/ml (IMX Tacrolimus, Abbott)

  3. Corticosteroids, e.g. prednisolone: The previous dosage is continued, but at least 5 mg prednisolone/day (or equivalent) must be given

Phase II: week 4.-9.

Randomisation at the beginning of week 4:

All patients receiving at least 3 x 500 mg MMF per day were randomised as follows Group A: Continuation of the triple therapy Group B: Elimination of CsA bzw. FK506 The ciclosporine A- or tacrolimus-dosage is reduced ba 33% each 2 weeks so that after 6-8 weeks a total elimination of the drugs is reached.

Phase III: week 10.-35.

Continuous therapy with...:

Group A: Triple therapy MMF / CsA bzw. FK506 / Corticosteroids e.g. Prednisolone Group B: Dual therapy MMF / Corticosteroids e.g. Prednisolone

Primary Endpoint:

Comparison of the development of 1/creatinine in both branches 32 weeks after randomization

Secondary Endpoints:

  • Occurrence of...

    • acute rejections
    • infections
    • malignomas
    • gastrointestinal disorders
  • Blood pressure evolution and number of antihypertensive drugs
  • Changes concerning the lipid state
  • Changes concerning the glucose metabolism
  • Changes in metabolism of uric acid
  • Comparison of the development of 1/creatinine within each branch 6 months before and 6 months after therapy conversion
  • Comparison of drop out rate in branches A und B
  • Pharmacokinetics of mycophenolic acid (MPA) based on a new method of abbreviated area under the curve (AUC) determination
  • vessel wall changes of the carotid arteries measured by high resolultion ultrasound methods and hemodynamic parameters measured by task force equipment before and 9 month after cni withdrawal and MMF addition

Criteria for study discontinuation:

  • Sepsis
  • Occurrence of acute rejections
  • Graft loss
  • Other severe adverse events
  • patients decision
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Immunosuppressive Agents
  • Kidney Failure, Chronic
  • Kidney Transplantation
Drug: mycophenolate mofetil (drug)
Not Provided
Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant. 2004 Apr;4(4):655-62.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
86
September 2002
Not Provided

Inclusion Criteria:

Written informed consent Reduction of graft function: Increase of serum creatinine >= 0,1mg/dl/month in the previous 6 months before start of the study and/or new occurrence or increasing proteinuria in the last 6 months before start of the study Serum creatinine < 4 mg/dl Biopsy within the last 3 months histologically proved chronic allograft nephropathy >=1 year after renal allografting >=5 mg/day Prednisolone or equivalent dose

Exclusion Criteria:

Malignomas Gravidity or Lactation Participation in other studies Severe infections gastrointestinal Ulcer Age <18 and >70 years Leukopenia with less that 3000/dl leucocytes, Anaemia Hb > 9 g/dl Therapy with mycophenolatmofetil in the past 6 months Acute rejections in the past 6 months

-

Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00204230
1
Not Provided
Not Provided
University Hospital Muenster
Hoffmann-La Roche
Principal Investigator: Barbara M Suwelack, PhD University Hospital
University Hospital Muenster
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP